CD37 and non-Hodgkin lymphoma: 177Lu-lilotomab satetraxetan or Betalutin® (Nordic Nanovector ASA, Oslo, Norway), which binds CD37, is a novel antibody-radionuclide conjugate for treatment of relapsed CD37+ indolent non-Hodgkin lymphoma which has been investigated in the first-in-human phase 1/2a study LYMRIT-37-01 [11].